Aldeyra Therapeutics announces positive results from Phase 2b dry eye disease clinical trial; statistically significant improvement across multiple symptom and sign measures
- Early onset and broad range of activity supports differentiated product profile.
- Pivotal clinical testing is expected to begin in 2019 following discussion with regulatory authorities.
- The randomized, vehicle-controlled, parallel-group, multi-center, double-masked Phase 2b clinical trial investigated 0.1% and 0.25% concentrations of reproxalap topical ophthalmic solution versus vehicle. Relative to patients treated with vehicle, patients treated with the 0.25% concentration of reproxalap had statistically significant and clinically relevant reductions in the Four-Symptom Ocular Dryness Score and the Overall Ocular Discomfort Symptom Score.
No comments:
Post a Comment